Furthermore, treatment with a combination of anti–PD-L1 and anti-CD73 enhanced TGI and T cell response against EGFR-mutated NSCLC tumors, compared with treatment with anti–PD-L1 alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.